alanine has been researched along with Renal Insufficiency, Chronic in 13 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
Renal Insufficiency, Chronic: Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Tenofovir alafenamide (TAF) may be preferable to other nucleos(t)ide analogues (NA) regarding outcomes against chronic hepatitis B virus (HBV) infection." | 8.12 | Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study. ( Amagase, H; Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Ichiki, Y; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Kuniyoshi, M; Morita, C; Nakamuta, M; Nomura, H; Ogawa, E; Ooho, A; Satoh, T; Shimoda, S; Sugimoto, R; Takahashi, K; Yamashita, N, 2022) |
| "Although tenofovir alafenamide (TAF) and besifovir dipivoxil maleate (BSV) are potent antiviral agents in the treatment of chronic hepatitis B (CHB) infection, their renal safety profiles have not been previously compared." | 8.12 | Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B. ( Ahn, SH; Jung, CY; Kim, BS; Kim, HW; Kim, SU; Lee, HW; Lee, JI, 2022) |
| "Tenofovir alafenamide (TAF) may be preferable to other nucleos(t)ide analogues (NA) regarding outcomes against chronic hepatitis B virus (HBV) infection." | 4.12 | Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study. ( Amagase, H; Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Ichiki, Y; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Kuniyoshi, M; Morita, C; Nakamuta, M; Nomura, H; Ogawa, E; Ooho, A; Satoh, T; Shimoda, S; Sugimoto, R; Takahashi, K; Yamashita, N, 2022) |
| "Although tenofovir alafenamide (TAF) and besifovir dipivoxil maleate (BSV) are potent antiviral agents in the treatment of chronic hepatitis B (CHB) infection, their renal safety profiles have not been previously compared." | 4.12 | Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B. ( Ahn, SH; Jung, CY; Kim, BS; Kim, HW; Kim, SU; Lee, HW; Lee, JI, 2022) |
| "Real-world data for treatment effectiveness and renal outcomes in chronic hepatitis B (CHB) patients who were switched to the new and safer prodrug tenofovir alafenamide (TAF) from tenofovir disoproxil fumarate (TDF) are limited." | 4.02 | Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice. ( Arai, T; Asai, A; Atsukawa, M; Cheung, R; Chien, N; Chuma, M; Dang, H; Fukunishi, S; Henry, L; Hoang, J; Huang, DQ; Ishikawa, T; Landis, C; Le, RH; Leong, J; Lim, SG; Liu, J; Maeda, M; Nguyen, MH; Quek, SXZ; Senoo, T; Takaguchi, K; Thin, KN; Toyoda, H; Tran, S; Trinh, HN; Uojima, H; Watanabe, T; Yasuda, S; Yokohama, K, 2021) |
| " This review summarizes the current data for the most commonly used drugs for coronavirus disease 2019 and will cover the unique factors that may affect the dosing of these medications in patients with CKD." | 2.66 | Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function. ( Govil, A; Luckett, K; Miller-Handley, H, 2020) |
| "Proteinuria is also now recognized as a common finding in individuals living with HIV." | 2.55 | Renal effects of novel antiretroviral drugs. ( Jones, R; Levy, JB; Milburn, J, 2017) |
| " Model-based simulations revealed 294% and 515% increases of median tenofovir Cmin in patients with CLCR of 15-29 mL/min (CKD stage 3), and less than 15 mL/min (stage 4), respectively, compared with normal renal function (CLCR = 90-149 mL/min)." | 1.91 | Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration. ( Alves Saldanha, S; Andre, P; Buclin, T; Cavassini, M; Courlet, P; Decosterd, LA; Desfontaine, V; Guidi, M; Kusejko, K; Thoueille, P, 2023) |
| " There were no discontinuations due to adverse events." | 1.43 | Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment. ( Custodio, JM; Fordyce, M; Garner, W; Kearney, BP; Ling, KH; Ramanathan, S; Vimal, M, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 9 (69.23) | 2.80 |
| Authors | Studies |
|---|---|
| Ogawa, E | 2 |
| Nakamuta, M | 2 |
| Koyanagi, T | 2 |
| Ooho, A | 2 |
| Furusyo, N | 2 |
| Kajiwara, E | 2 |
| Dohmen, K | 2 |
| Kawano, A | 2 |
| Satoh, T | 2 |
| Takahashi, K | 2 |
| Azuma, K | 2 |
| Yamashita, N | 4 |
| Sugimoto, R | 2 |
| Amagase, H | 2 |
| Kuniyoshi, M | 2 |
| Ichiki, Y | 2 |
| Morita, C | 2 |
| Kato, M | 2 |
| Shimoda, S | 2 |
| Nomura, H | 2 |
| Hayashi, J | 2 |
| Jung, CY | 1 |
| Kim, HW | 1 |
| Lee, JI | 1 |
| Lee, HW | 1 |
| Ahn, SH | 1 |
| Kim, SU | 1 |
| Kim, BS | 1 |
| Nakade, Y | 2 |
| Iwata, Y | 2 |
| Sakai, N | 2 |
| Mita, M | 2 |
| Nakane, M | 2 |
| Hamase, K | 2 |
| Suda, W | 2 |
| Toyama, T | 2 |
| Kitajima, S | 2 |
| Hara, A | 2 |
| Shimizu, M | 2 |
| Ogushi, C | 2 |
| Furuichi, K | 2 |
| Koshino, Y | 2 |
| Morita, H | 2 |
| Hattori, M | 2 |
| Wada, T | 2 |
| Thoueille, P | 1 |
| Alves Saldanha, S | 1 |
| Desfontaine, V | 1 |
| Kusejko, K | 1 |
| Courlet, P | 1 |
| Andre, P | 1 |
| Cavassini, M | 1 |
| Decosterd, LA | 1 |
| Buclin, T | 1 |
| Guidi, M | 1 |
| Roberto, P | 1 |
| Francesco, L | 1 |
| Emanuela, C | 1 |
| Giorgia, G | 1 |
| Pasquale, N | 1 |
| Sara, D | 1 |
| Bruchfeld, A | 1 |
| Miller-Handley, H | 1 |
| Luckett, K | 1 |
| Govil, A | 1 |
| Toyoda, H | 1 |
| Leong, J | 1 |
| Landis, C | 1 |
| Atsukawa, M | 1 |
| Watanabe, T | 1 |
| Huang, DQ | 1 |
| Liu, J | 1 |
| Quek, SXZ | 1 |
| Ishikawa, T | 1 |
| Arai, T | 1 |
| Yokohama, K | 1 |
| Chuma, M | 1 |
| Takaguchi, K | 1 |
| Uojima, H | 1 |
| Senoo, T | 1 |
| Dang, H | 1 |
| Maeda, M | 1 |
| Hoang, J | 1 |
| Le, RH | 1 |
| Yasuda, S | 1 |
| Thin, KN | 1 |
| Tran, S | 1 |
| Chien, N | 1 |
| Henry, L | 1 |
| Asai, A | 1 |
| Fukunishi, S | 1 |
| Cheung, R | 1 |
| Lim, SG | 1 |
| Trinh, HN | 1 |
| Nguyen, MH | 1 |
| Vigorito, C | 1 |
| Anishchenko, E | 1 |
| Mele, L | 1 |
| Capolongo, G | 1 |
| Trepiccione, F | 1 |
| Zacchia, M | 1 |
| Lombari, P | 1 |
| Capasso, R | 1 |
| Ingrosso, D | 1 |
| Perna, AF | 1 |
| Milburn, J | 1 |
| Jones, R | 1 |
| Levy, JB | 1 |
| Custodio, JM | 1 |
| Fordyce, M | 1 |
| Garner, W | 1 |
| Vimal, M | 1 |
| Ling, KH | 1 |
| Kearney, BP | 1 |
| Ramanathan, S | 1 |
| Yoshihara, A | 1 |
| Sugita, N | 1 |
| Iwasaki, M | 1 |
| Wang, Y | 1 |
| Miyazaki, H | 1 |
| Yoshie, H | 1 |
| Nakamura, K | 1 |
4 reviews available for alanine and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Current treatment of COVID-19 in renal patients: hope or hype?
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Antibodies, Monoclonal; Cobicista | 2020 |
The COVID-19 pandemic: consequences for nephrology.
Topics: Acute Kidney Injury; Adenosine Monophosphate; Alanine; Antiviral Agents; COVID-19; COVID-19 Drug Tre | 2021 |
Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function.
Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanize | 2020 |
Renal effects of novel antiretroviral drugs.
Topics: Adenine; Alanine; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Creatinine; Disease Progression; | 2017 |
9 other studies available for alanine and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; DNA, Viral; Female; Hepatitis B Surface Antigens | 2022 |
Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study.
Topics: Adenine; Adult; Alanine; Antiviral Agents; DNA, Viral; Hepatitis B, Chronic; Humans; Renal Insuffici | 2022 |
Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Guanine; Hepatitis B; Hepatitis B, Chronic; Humans; Kidney; Long | 2022 |
Increased levels of oral Streptococcus-derived D-alanine in patients with chronic kidney disease and diabetes mellitus.
Topics: Adult; Alanine; Bacteria; Diabetes Mellitus; Humans; Renal Insufficiency, Chronic; RNA, Ribosomal, 1 | 2022 |
Increased levels of oral Streptococcus-derived D-alanine in patients with chronic kidney disease and diabetes mellitus.
Topics: Adult; Alanine; Bacteria; Diabetes Mellitus; Humans; Renal Insufficiency, Chronic; RNA, Ribosomal, 1 | 2022 |
Increased levels of oral Streptococcus-derived D-alanine in patients with chronic kidney disease and diabetes mellitus.
Topics: Adult; Alanine; Bacteria; Diabetes Mellitus; Humans; Renal Insufficiency, Chronic; RNA, Ribosomal, 1 | 2022 |
Increased levels of oral Streptococcus-derived D-alanine in patients with chronic kidney disease and diabetes mellitus.
Topics: Adult; Alanine; Bacteria; Diabetes Mellitus; Humans; Renal Insufficiency, Chronic; RNA, Ribosomal, 1 | 2022 |
Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration.
Topics: Adenine; Alanine; Anti-HIV Agents; HIV Infections; Humans; Renal Insufficiency, Chronic; Tenofovir | 2023 |
Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice.
Topics: Adult; Aged; Alanine; Alanine Transaminase; DNA, Viral; Drug Substitution; Female; Glomerular Filtra | 2021 |
Uremic Toxin Lanthionine Interferes with the Transsulfuration Pathway, Angiogenetic Signaling and Increases Intracellular Calcium.
Topics: Alanine; Amino Acids, Sulfur; Calcium; Cell Line; Cystathionine beta-Synthase; Endothelial Cells; Fl | 2019 |
Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment.
Topics: Adenine; Aged; Alanine; Anti-HIV Agents; Area Under Curve; Case-Control Studies; Female; Glomerular | 2016 |
Relationship between renal function and periodontal disease in community-dwelling elderly women with different genotypes.
Topics: Aged; Alanine; Alleles; Arginine; Body Mass Index; Case-Control Studies; Cystatin C; Female; Genotyp | 2017 |